Bortezomib + Isatuximab + Iberdomide + Lenalidomide + Dexamethasone
Phase 3Recruiting 1 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Newly Diagnosed Multiple Myeloma
Conditions
Newly Diagnosed Multiple Myeloma
Trial Timeline
Oct 1, 2022 → Apr 1, 2029
NCT ID
NCT05558319About Bortezomib + Isatuximab + Iberdomide + Lenalidomide + Dexamethasone
Bortezomib + Isatuximab + Iberdomide + Lenalidomide + Dexamethasone is a phase 3 stage product being developed by Bristol Myers Squibb for Newly Diagnosed Multiple Myeloma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05558319. Target conditions include Newly Diagnosed Multiple Myeloma.
What happened to similar drugs?
0 of 4 similar drugs in Newly Diagnosed Multiple Myeloma were approved
Approved (0) Terminated (1) Active (3)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05558319 | Phase 3 | Recruiting |
Competing Products
18 competing products in Newly Diagnosed Multiple Myeloma